Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07474792
PHASE2

Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis

Sponsor: Oruka Therapeutics, Inc.

View on ClinicalTrials.gov

Summary

This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-002 in adult participants with moderate-to-severe plaque psoriasis.

Official title: A Multicenter, Randomized, Double-Blinded, Placebo- Controlled, Dose-Range Finding Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ORKA-002 in Participants With Moderate-to-Severe Plaque Psoriasis

Key Details

Gender

All

Age Range

18 Years - 79 Years

Study Type

INTERVENTIONAL

Enrollment

160

Start Date

2026-03

Completion Date

2029-04

Last Updated

2026-03-16

Healthy Volunteers

No

Interventions

DRUG

ORKA-002

ORKA-002 administered by subcutaneous (SC) injection

OTHER

Placebo

Placebo administered by subcutaneous (SC) injection